Skip to content

Incanthera PLC - Investor Presentation


Announcement provided by

Incanthera plc · INC

17/06/2024 07:00

Incanthera PLC - Investor Presentation
RNS Number : 5717S
Incanthera PLC
17 June 2024
 

 

 

Goal Group

 

                                                                                17 June 2024

 

Incanthera plc

("Incanthera" the "Company")

Investor Presentation

 

Shares Investor Evening in Partnership with AJ Bell

 

Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, announces that it will be presenting at Shares Investor Evening in partnership with AJ Bell, in London at 5.30 p.m. on Tuesday 18 June 2024 to an audience of high net worth investors, fund managers, private client brokers and analysts.

 

Incanthera will be delivering a hand-out investor presentation.  The presentation, which will not contain any inside information, will be made available shortly on its website, www.incanthera.com.

 

RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

 

For further information please contact:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600



Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

 

 

 

 

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                               

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEZLFFZQLZBBX]]>

View more ...

INC announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal